Literature DB >> 3128948

Myasthenia gravis with thymoma and pure red blood cell aplasia.

R O Bailey1, H G Dunn, A M Rubin, A L Ritaccio.   

Abstract

A case of myasthenia gravis with histopathologic confirmation of spindle cell thymoma and pure red blood cell aplasia is reported. This is the twelfth case in the literature in which a simultaneous occurrence of all three disorders, with documented thymic pathology, is noted. Immunologic observations in this patient include an elevated acetylcholine receptor antibody and antinuclear antibody titer, agglutination of mouse red blood cells when combined with the patient's serum, and lack of inhibition of binding of radioactive erythropoietin to mouse red cell receptors when combined with the patient's serum. Although both myasthenia with thymoma and pure red blood cell aplasia may have a common immunologic denominator, our findings in this case indicate that inhibition of erythropoiesis is unrelated to erythropoietin receptor blockade. An alternative hypothesis is offered based on defective T-cell function.

Entities:  

Mesh:

Year:  1988        PMID: 3128948     DOI: 10.1093/ajcp/89.5.687

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  3 in total

1.  Triad of thymoma, myasthenia gravis and pure red cell aplasia combined with Sjögren's syndrome.

Authors:  Koichi Fujiu; Ryuzo Kanno; Yutaka Shio; Jyun Ohsugi; Yoshihiro Nozawa; Mitsukazu Gotoh
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2004-07

2.  Pure red cell aplasia associated with malignant thymoma, myasthenia gravis, polyclonal large granular lymphocytosis and clonal thymic T cell expansion.

Authors:  S I Handa; K P Schofield; M Sivakumaran; M Short; R S Pumphrey
Journal:  J Clin Pathol       Date:  1994-07       Impact factor: 3.411

3.  Rational management approach to pure red cell aplasia.

Authors:  Suresh Kumar Balasubramanian; Meena Sadaps; Swapna Thota; Mai Aly; Bartlomiej P Przychodzen; Cassandra M Hirsch; Valeria Visconte; Tomas Radivoyevitch; Jaroslaw P Maciejewski
Journal:  Haematologica       Date:  2017-12-07       Impact factor: 9.941

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.